Clinical Trial Update: A Study of TAS-120 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of futibatinib (TAS-120) in patients with advanced solid tumors, including cholangiocarcinoma, urothelial carcinoma, breast cancer, gastric ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Central Nervous System Tumors
• Cholangiocarcinoma
• Gastric Cancer
• Urothelial Carcinoma

Drugs mentioned

• TAS-120 (futibatinib)

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: Cholangiocarcinoma, Urothelial Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-03-20